Approximately US $135 million, or the equivalent of 1.375 billion Swedish krona, has been newly invested by AstraZeneca into its Sweden Biomanufacturing Center in Södertälje, the company announced in a press release* on Aug. 26, 2024. The money will help expand the functional area of the Södertälje campus by 50%, adding 2700 square meters to an existing building. Once the completion of the expanded facility is finalized, AstraZeneca said, manufacturing of products for patients will begin in the new section, which could be as early as the fourth quarter of 2027. Source: Biopharm International 4/9/2024